
Victoria Costa Paz on Making Biotech Work Beyond the Lab
Victoria Costa Paz is building Eywa Biotech around a difficult challenge: producing pharmaceutical-grade psilocybin through fermentation at a commercially viable scale. She joins Mark Sephton to discuss the technical and financial obstacles of biomanufacturing, how her fintech background influences her approach, and why data analysis is essential to improving production. Costa Paz also explains how Eywa's WALO platform could support psychedelic-assisted therapy and why collaboration across manufacturers, clinicians, and technology companies matters for the industry's future.












